A PHASE II STUDY OF TRI-WEEKLY PANITUMUMAB REGIMEN AS A THIRD-LINE THERAPY FOR PATIENTS WITH ADVANCED COLORECTAL CANCER

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose

Panitumumab is one of standard treatments for patients with advanced colorectal cancer. Panitumumab is administered bi-weekly, but there are a few profiles of safety and efficacy for tri-weekly treatment of panitumumab. Nowadays, oxaliplatin or irinotecan with fluoropyrimidines is widely used as tri-weekly treatment like XELOX. So a clinical trial for tri-weekly panitumumab regimen is warranted, because of to develop of tri-weekly regimen like XELOX with panitumumab. Therefore, we conduct a phase II study of tri-weekly panitumumab for patients with advenced colorectal cancer.

Methods

Patients who had received prior oxaliplatin, irinotecan and fluoropyrimidines treatment were eligible. Panitumumab at a dose of 9mg/kg was administered as 60-min infusion on day 1 every 3 weeks until progression or severe toxicity.

Results

This trial is still continued, and 5 patients were enrolled until January 2012. Age (range) is 57–74. Two patients were male. All patiens are ECOG PS 1 at a registration. All patients received over 4 cycles. None of patients was discontinued by adverse events. There was no treatment related death. Grade 3/4 fatigue, hypomagnesemia and anemia were observed in each one patient. Grade 2 skin disorder was observed in one patient. There was no severe diarrhea. One patient had partial response, and two patients had stable disease. The range of the duration of response time was 62–198 days. We will add the latest report on the meeting.

Related Topics

    loading  Loading Related Articles